What is it about?
The present review discusses the pathophysiology of the MDM2-p53 interaction loop and MDM2/MDM2-p53 interaction inhibitors from the literature, including patents. Focus has also been put on characteristic features of the active site of the target and its desired interactions with the currently FDA-approved inhibitor. The designing approach of previously reported MDM2/MDM2-p53 interaction inhibitors, their SAR studies, in silico studies, and the biological efficacy of various inhibitors from natural as well as synthetic origins have also been elaborated. An attempt has also been made to cover recently patented MDM2/MDM2-p53 interaction inhibitors.
Featured Image
Why is it important?
The present review is a crucial set of knowledge in the concerned domain and will help the researchers working in the field to rationally design newer medicinal agents to inhibit MDM2/p53 interactions and effectively treat cancer.
Read the Original
This page is a summary of: Recent Advancements in the Discovery of MDM2/MDM2-p53 Interaction
Inhibitors for the Treatment of Cancer, Current Medicinal Chemistry, October 2023, Bentham Science Publishers,
DOI: 10.2174/0929867330666221114103924.
You can read the full text:
Contributors
The following have contributed to this page
